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Abstract
The central importance of tumour neovascularization has been
emphasized by clinical trials using antiangiogenic therapy in breast
cancer. This review gives a background to breast tumour neo-
vascularization in in situ and invasive breast cancer, outlines the
mechanisms by which this is achieved and discusses the influence
of the microenvironment, focusing on hypoxia. The regulation of
angiogenesis and the antivascular agents that are used in an
antiangiogenic dosing schedule, both novel and conventional, are
also summarized.
Introduction
It has been 3 years since the last critical review of anti-
angiogenic therapy was published in Breast Cancer Research
[1], and since then the central importance of tumour
neovascularization has been emphasized by clinical trials in
various tumour types, including breast cancer. Many of these
trials have used bevacizumab (Avastin™; Genentech, South
San Francisco, CA, USA), which was specifically designed to
target vascular endothelial cell growth factor (VEGF).
Bevacizumab is a recombinant VEGF antibody derived from a
humanized murine monoclonal antibody that can recognize all
known isoforms of VEGF-A and prevents receptor binding,
thereby inhibiting angiogenesis and tumour growth. The critical
contribution of this angiogenic factor in controlling many of the
processes involved in angiogenesis and its importance as a
paradigm for the rational design of an anticancer agent have
been among the successes of antiangiogenic treatment, which
was first suggested by Judah Folkman more than 35 years ago.
The attractiveness of the antiangiogenic approach has always
been the wide therapeutic window, since all tumours (including
liquid such as leukaemias) are angiogenesis dependent, that
angiogenesis is highly restricted in the adult, that endothelium
of the vessels are accessible and that any treatment would be
amplified through subsequent tumour infarction. Furthermore,
the erstwhile problem in oncology of resistance should not be
an issue because endothelial cells are non-neoplastic and
should have a stable genome [2].
Nevertheless, although these trials have demonstrated signifi-
cant improvements in response rates, findings to date have
not indicated substantial benefits in terms of survival. This is
likely to be due to redundancy in breast tumours with an
individual tumour being able to utilise several angiogenic
pathways at any one time [3] with changes in this profile
during tumour progression coupled with the use of other
mechanisms to establish a blood supply. Indeed, the central
tenet that tumours are angiogenesis dependent (in that for a
tumour to grow, this must be preceded by a wave of
angiogenesis to deliver nutrients and meet the metabolic
requirements of the growing tumour) has been challenged.
Thus, a number of nonangiogenic mechanisms may contri-
bute to establishing tumour blood supply; these include co-
option, vasculogenesis, vascular remodelling, intussusception
and vascular mimicry.
A further important issue that has not been addressed is
stratification of patients for appropriate treatment; specifically,
individual patients given antiangiogenic agents have yet to be
selected based on the characteristics of their tumour. It is
therefore likely, as has been demonstrated for other targeted
agents such as herceptin, that benefit will be restricted to
those patients whose tumours rely largely on VEGF signalling
for their angiogenic response. The administration of agents
based on the biology of the individual tumour (so-called per-
sonalized medicine) will become increasingly important not
only to generate maximum therapeutic benefit to the patient
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Breast tumour neovascularization
Angiogenesis in the normal human adult is highly restricted,
largely to wound healing and reproduction. Sustained
angiogenesis is pathological and is characteristic of many
common diseases, including diabetes, psoriasis and
rheumatoid arthritis [4]. Thus, in order to initiate neovas-
cularization, a tumour must switch to an angiogenic pheno-
type. Evidence from transgenic models that have repro-
ducible distinct tumour stages suggest that the acquisition of
this phenotype occurs early in tumour development and that it
is rate limiting with regard to tumour progression [5,6]. These
experimental models are supported by findings in human
tissues, in which 30% of transplanted human hyperplastic
breast tissue samples were found to be angiogenic as
compared with only 3% of samples from normal breast tissue
[7-9]. Interestingly, normal breast adjacent to malignant
breast induced angiogenesis twice as frequently as did
tissues from non-neoplastic breast, suggesting that the
angiogenic switch occurs before morphological changes are
identifiable [10]. Using microvessel density as a surrogate for
angiogenesis, benign lesions associated with high vascular
density are correlated with increased risk for developing
breast cancer. It has also been suggested that quantification
of angiogenesis might help to predict the likelihood that in
situ cancers will progress [11,12] or that a tumour will
respond to treatment [13-17], and has been shown to
correlate directly with the presence of bone marrow
micrometastases [18] and survival [19,20].
Although it is likely that different tumour types use different
genetic pathways to establish a blood supply, oncogenes
and tumour suppressor genes that are frequently associated
with transformation also appear to be important in activating
the angiogenic switch. Thus, Ras, myc, raf, c-erbB-2, c-jun
and src transformed cells exhibit a strong angiogenic
phenotype [21-24]. However, the vessels formed under the
influence of these pathways are abnormal, leaky with blind
sacs, and have reversed and intermittent flow [25]. The result
is that although there is an increase in formation of new
vessels, drug and oxygen delivery is much poorer than in
normal tissues. This leads to hypoxia and microenvironmental
stresses that have been demonstrated to have profound
effects on tumour biology and resistance to treatment [26].
The microenvironmental influence of hypoxia
Hypoxia is the pathophysiological consequence of a
structurally and functionally disturbed microcirculation [26],
and it is therefore a common feature in solid tumours.
Tumours respond to low oxygen tension by enhancing the
hypoxia-inducible factor (HIF) response [27]. The HIF
response is mediated through the transcription factor dimer
inducible HIF-1α and constitutively expressed HIF-1β (also
known as aryl hydrocarbon nuclear translocator).
In normoxia, three prolyl hydroxylases (prolyl hydroxylase-1, -2
and -3) hydroxylate HIF-1α at two proline residues in its
oxygen-dependent degradation domain, with oxoglutarate
from the Krebs cycle, ascorbate and Fe2+ leading to
recognition and binding of the α domain by the von Hippel-
Lindau protein. This interaction, and through binding of
elongin C via von Hippel-Lindau β domain in turn, leads to
ubiquitination and targeting for degradation through the
proteasome. In conditions of hypoxia, however, molecular
oxygen is not available for hydroxylation which results in
HIF-1α stabilization and translocation to the nucleus, where it
binds to HIF-1β and consensus hypoxia response elements
on gene promoters. Co-activators and polymerases are
recruited and transcriptional activation of several gene
pathways that are involved in angiogenesis, glycolysis,
erythropoiesis and apoptosis occurs. The asparagine
hydroxylase, factor inhibitor of HIF-1, and CITED4 (CBP
p300-interacting transactivator 4), which interfere with co-
activator binding, provide a further level of control [28,29].
Over-expression of HIF-1α protein has been identified in
various tumour types, with high levels influencing the growth
rate and metastatic potential of these cancers. In breast
cancers, the frequency of HIF-1α positive cells increases in
parallel with increasing clinical stage and is associated with
poor prognosis [30-33]. In addition to HIF-1α, other isoforms
have been identified, namely HIF-2α and HIF-3α [34,35]. The
roles played by these isoforms are complex, but there is
evidence that the latter antagonizes hypoxia-dependent gene
expression, whereas the former can enhance the hypoxic
response element. Interestingly, there is evidence that HIF-1α
and HIF-2α activate different sets of hypoxia-inducible genes
[36], including those involved in glycolysis, cell survival and
proliferation [37]. However, the clinical relevance to breast
cancer is not known because there are only limited data on
these HIF isoforms. Thus, in breast cancer HIF-2α has been
reported to be expressed in both tumour cells [38] and in
tumour-associated macrophages (TAMs) [39]. TAM HIF-2α
expression was found to be related to tumour vascularity,
suggesting that hypoxia induces TAM clustering and over-
expression of TAM HIF-2α, thereby inducing an angiogenic
phenotype, leading to induction of localized angiogenic hot
spots [39]. Thus, hypoxic stress response through HIF is
likely to be an important mechanism by which continued
remodelling of vessels occurs.
Recognition that HIF plays a significant role in tumour
behaviour, conferring an aggressive phenotype and contri-
buting to resistance to both radiotherapy and chemotherapy
[40], has led to efforts to target the HIF pathway. Several
trials of agents that decrease and/or block HIF-1α expres-
sion, including rapamycin/CCI779, quinocarmycin, topoiso-
merase inhibitors, anti-microtubular agents, YC-1, 17-AAG,
thioredoxin inhibitors and 2ME2, have been conducted or are
planned [41]. Other potential targets in HIF signalling include
the molecules that are involved in oxygen sensing or trans-
cription. For instance, obstructing the interaction between
HIF-1α and the co-activator CBP/p300 led to attenuation ofPage 3 of 11
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HIF-induced gene expression and inhibition of tumour growth
in a xenograft model [42]. An alternative strategy is to use the
HIF pathway to activate bioreductive drugs such as tirapaza-
mine, which inhibits DNA repair under hypoxic condition [43]
and has been shown to have an antiangiogenic effect as well
as direct antitumour activity [44]. Correction of the hypoxic
environment by reducing anaemia [45] using human
recombinant erythropoietin is also a potentially effective
approach.
Mechanisms of neovascularization
Although sprouting-type angiogenesis is an important mecha-
nism in tumour neovascularization, several other mechanisms
by which tumours establish a blood supply have been identi-
fied; these include vascular remodelling, vasculogenesis,
vascular mimicry and glomeruloid angiogenesis. Each may
have significance in a particular tumour type or at a particular
stage of tumour evolution, but the relative importance of each
in human tumours is unknown. However, angiogenesis and
vascular remodelling appear to be the major mechanisms in
breast cancer with evidence that vascular mimicry may
additionally play a role in inflammatory breast cancer. The
acquisition of this type of biological information is likely to
become more important as patients are treated in a more
individuallized manner. Although microvessel density has
been used as a surrogate for angiogenesis, many other
parameters of tumour neovascularization have also been
explored, including angiogenic factor expression, cell
adhesion molecules, vessel maturation and endothelial cell
proliferation [19]. These measures, including microvessel
density, have associated problems [46] and none provides a
reliable measure of blood flow, which is extremely variable
because of shunting, stasis and even reverse flow occurring
through the abnormal tumour vasculature [47].
Angiogenesis
Angiogenesis is the generation of new blood vessels from the
existing vasculature. It consists of multiple coordinated,
sequential and interdependent steps. The angiogenic pro-
gramme requires the degradation of the basement membrane,
endothelial cell migration and invasion of the extracellular
matrix, with endothelial cell proliferation and capillary lumen
formation before maturation and stabilization of the new
vasculature. The latter requires inhibition of further endothelial
proliferation, reconstitution of the basement membrane, and
junctional complex formation and organization of endothelial
cells into a new luminal space.
Vascular remodelling
In contrast to animal models in which endothelial cells
proliferate 30-fold to 40-fold faster in tumour blood vessels
than in the vasculature of normal tissue, irrespective of
tumour type, growth rate, or size, endothelial cell proliferation
in human breast tumours is relatively rare. The corollary of this
finding is that vascular remodelling must be the dominant
mechanism in establishing the neovasculature in breast
cancers [48-50]. This can occur through a variety of
processes including co-option, in which tumours hijack the
existing vasculature. This has been reported early in brain
tumour development, in which existing blood vessels are
used in the absence of an angiogenic response [51,52],
although continued tumour growth results in angiogenesis.
The tie2-angiopoietin and VEGF growth factor pathways may
regulate these respective mechanisms of tumour vasculariza-
tion. Thus, in some circumstances tumours are able to
‘parasitize’ the normal stroma and sinusoidal vasculature for
its metabolic needs.
Intussusception of tumour columns has also been hypothe-
sized to contribute to the establishment of a tumour blood
supply. This process is independent of endothelial cell
proliferation and is rapid, depending on insertion of tissue
pillars into vessels, partitioning the vessel lumen into two or
more channels [53,54]. This may be part of vascular
remodelling, which may be the dominant mechanism in the
establishment of the tumour vascular bed.
Vasculogenesis
Vasculogenesis is the de novo generation of blood vessels
from endothelial cell progenitors, as occurs in the embryo. In
animal models it has been demonstrated that circulating
endothelial cell precursors derived from the bone marrow
lodge in the cancer vasculature, differentiate into endothelial
cells and enhance tumour neovascularization through a
combination of vasculogenesis and conventional angio-
genesis [55-58]. There appear to be differences in the
proportion of tumour neovascularization that can be
apportioned to vasculogenesis, depending on the model (up
to 90%). In orthoptic models this appears to account for
<5% and in human tumours had an average of 4.9% (range
1-12%) when examining tumours from transplant recipients
[59,60].
There is evidence to suggest that this process of tumour
vascularization may be more frequent and/or significant in
early tumour development because inhibition of stem cells or
endothelial cell precursor mobilization prevents xenografts
from inducing the initial angiogenic response [61]. Never-
theless, there is some debate as to whether such bone
marrow derived endothelial cells are actually incorporated
into the vasculature and whether they may be acting in a
paracrine/support function [62]. The discrepancies between
reported findings may be due to replacement of bone marrow
derived cells with surrounding endothelial cells with tumour
progression [63]. The two models may not be mutually
exclusive because several different populations of cells have
been reported that may be involved in a support and integral
role (for instance, macrophages/monocytes, myeloid pro-
genitors, platelet/megakaryocyte lineages, pericyte progenitors,
neutrophils and so-called vascular leucocytes, which express
mixed endothelial and white cell lineages). Regulation of
these processes may be through angiogenic factors such as
Available online http://breast-cancer-research.com/content/9/6/216VEGF, which mobilizes precursor cells from the bone
marrow, but there are some data to suggest that the
subsequent retention of these progenitor cells may require
additional factors such as stromal-derived factor 1 [64].
Interestingly, stromal-derived factor 1 is hypoxia inducible via
HIF [65]. There are few data in breast, but it has been
suggested that vasculogenesis occurs in inflammatory
subtype breast tumours [66].
Glomeruloid angiogenesis
Glomeruloid bodies that are characteristic of glioblastomas
are also observed in invasive breast cancers [67]. These are
highly complex vascular aggregates that resemble glomeruli
of the kidney, composed of a network of capillaries that are
variably lined by basement membrane and pericytes. Their
presence is associated with a significantly shorter survival in
breast (and other) cancers [68]. Their formation is related to
VEGF, because this angiogenic factor is not only essential for
their induction but also for maintenance of these bodies [69].
We have also observed these in breast cancer xenografts
transfected with VEGF [70]. This type of tumour neo-
vascularization may also represent vascular remodelling
rather than classical sprouting-type angiogenesis [71].
Vascular mimicry
Vascular mimicry is a neovascularization strategy that may
largely be restricted to aggressive occular malignant mela-
nomas and ovarian tumours [72], but it has also been
reported in breast cancers [66]. Partial lining of the capillary
surface by tumour cells has been known for many years [73]
and was more recently reported in animal models using
advanced techniques [74], but vascular mimicry is defined as
a complete capillary network composed of tumour cells
themselves rather than vascular endothelial cells that
conducts blood [75,76]. The tumour cells not only take on
the morphology of endothelial cells but they also acquire
phenotypic characteristics of endothelium, expressing a
number of vascular markers. It is important to recognize this
type of neovascularization because the therapeutic implica-
tions of having mimicry as a dominant mechanism are that
these tumours may not respond to conventional anti-
angiogenic agents.
Angiogenic factors in breast cancer
Whatever the mechanism(s) that a tumour use(s) to establish
a blood supply, similar regulatory factors are utilized (although
some may preferentially be used in particular processes). The
presence of a humoral mediator of tumour angiogenesis was
suggested more than 60 years ago, but it was not until 1968
that it was demonstrated that a diffusible tumour-derived
factor could induce capillary growth [77,78]. Folkman and
coworkers [79] reported the first angiogenic factor, namely
tumour angiogenesis factor; this discovery was followed by
identification of numerous other angiogenic promoters and
inhibitors [80,81]. Most have pleiotropic effects, and the role
played by many in human tumours is unknown. However,
several important angiogenic pathways have been implicated
in human tumour neovascularization.
The angiogenic promoters and inhibitors that underlie
establishment of a tumour blood supply through the above-
mentioned mechanisms of neovasculrization can originate
from the neoplastic cell and/or from other tumour elements.
Thus, neoplastic cells can recruit inflammatory cells such as
macrophages and mast cells, both of which are rich sources
of angiogenic factors and cytokines, or they can induce
release of sequestered growth factors or their receptors from
the extracellular matrix through protease degradation.
Platelets, which also are a rich source of angiogenic factors
and are often elevated in malignancy, can be activated by
tumour endothelium or epithelium.
Invasive and in situ breast cancers express many angiogenic
factors, including the VEGF family (see below), fibroblast
growth factor (FGF)-1, FGF-2, placenta growth factor, trans-
forming growth factor-β1, thymidine phosphorylase, pleio-
trophin and adrenomedullin [3,82,83]. However, these are
expressed preferentially at different stages of tumour
development. Hence, thymidine phosphorylase is expressed
in in situ [84] and T1 breast tumours [85], whereas VEGF
expression occurs throughout the tumour stages. Further-
more, breast cancers are likely to express different angio-
genic profiles, which will necessitate the use of a different
spectrum of antiangiogenic agents.
VEGF and anti-VEGF therapies
VEGF
Studies have shown that the VEGF family plays a central role
in many human tumour types (for review [81]). Comprising
VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth
factor, these polypeptides exist in a number of isoforms and
can form homodimers and heterodimers. They bind variably to
three high-affinity endothelial cell tyrosine kinase receptors,
namely Flt-1 (VEGF receptor [VEGFR]1), KDR (VEGFR2)
and Flt-4 (VEGFR3), which are responsible for initiating
intracellular signalling. Receptor activation results in slightly
different effects, with VEGFR1 promoting differentiation and
vascular maintenance, VEGFR2 inducing endothelial cell
proliferation  and vascular permeability, and VEGFR3
stimulating lymphangiogenesis. Additional regulation is
achieved through the isoform-specific receptors neuropilin-1
and neuropilin-2. The neuropilins bind not only class 3
semaphorins, which are involved in axonal growth, but also
some isoforms of VEGF, where they function as co-receptors,
increasing VEGF binding to VEGFR2 [86]. Further modulation
is achieved by proteolytic processing and/or heparin, which is
not only required for binding of VEGF (and basic FGF) but can
also compete for receptor sites. This complex pathway
enables the VEGFs to have numerous effects, including
increasing vascular permeability (thereby augmenting tumour
stroma formation), endothelial cell proliferation, endothelial cell
survival and tube formation. Although VEGFR expression is
Breast Cancer Research    Vol 9 No 6 Fox et al.
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also been reported on inflammatory cells such as
macrophages and tumour cells themselves.
VEGF-A is highly expressed in many tumours of lung, brain,
and gastrointestinal and urogenital tracts, as well as in situ
and invasive breast cancers [81]. Expression in some studies
is associated with microvessel density and prognosis,
supporting the importance of VEGF-A in human malignan-
cies. VEGF has a hypoxic response element in its promoter
and is one of several genes that are upregulated in a low
oxygen microenvironment to elicit a vascular phenotype.
However, the role played by the other family members in
human disease is still being elucidated and if tumours are
unable to express VEGF-A, other VEGF homologues may be
induced to augment neo-vessel formation. VEGF-B, VEGF-C
and VEGF-D are also expressed in breast cancers, with some
pathological correlates with nodal metastases, prognosis and
lymphatic density [87-94]. This may be important for two
reasons. First, there is large-scale redundancy in blood
supply to any tumour, allowing them to switch angiogenic
pathways; this suggests that there is a need for several or
multifunction agents. Second, many of these angiogenic
factors may synergize with each other (for instance, VEGF-A
and FGF-2), at least in vitro.
Anti-VEGF therapy
Although there are many ‘antiangiogenic’ targets for
anticancer therapies, many therapies have directly targeted
the VEGF pathway because of its critical role in pathological
angiogenesis and its profound influence of this growth factor
on endothelial biology. Many points on the pathway can be
targeted, including direct targeting of ligand and receptor
(extracellular and intracellular tyrosine kinase domains) at the
protein and mRNA levels, interfering with downstream
intermediates, and indirect inhibition of upstream regulators
of VEGF.
Bevacizumab
The most investigated agent to date is bevacizumab
(Avastin™; Genentech). Bevacizumab is a recombinant VEGF
antibody derived from a humanized mouse monoclonal
antibody (93% human) that is composed of the mouse
VEGF-binding site joined to a human IgG framework.
Bevacizumab recognizes all isoforms of VEGF-A and thereby
prevents receptor binding, which leads to inhibition of
angiogenesis and tumour growth. In vitro bevacizumab
inhibits VEGF-induced endothelial cell proliferation and
migration, and in xenograft models of a range of tumour types
(including breast cancer) tumour growth is significantly
decreased by bevacizumab [95,96]. In some human breast
carcinoma models, treatment with bevacizumab is associated
with a reduction in microvessel density [97].
In phase I/II clinical trial of 75 patients with metastatic breast
cancer treated with bevacizumab [98] there was an overall
response rate of 9.3% (confirmed response rate 6.7%) with a
median duration of 5.5 months (range 2.3 to 13.7 months);
16% had stable disease or an ongoing response at the end
of the trial (after 22 weeks). These data supported the
initiation of a phase III clinical trial that combined bevacizu-
mab with capecitabine in patients previously treated with an
anthracyclin and a taxane. Although the combination therapy
resulted in a statistically significantly increased response rate
(19.8% versus 9.1%), neither progression-free nor overall
survival differed between arms. Although there are many
explanations for the lack of success in terms of the primary
end-point of the study, the absence of patient selection
(specifically, of those patients whose tumours rely on VEGF)
is probably of great importance, in that advanced tumours
have redundancy in their ability to establish a blood supply
and utilize many pathways. There is ongoing analysis of
primary tumour samples for pathological factors that might
predict response to bevacizumab in this study.
Nevertheless, a phase III first-line trial comparing bevacizu-
mab plus paclitaxel versus paclitaxel alone in patients with
locally recurrent or metastatic breast cancer [99] revealed
that this combination increased significantly response rates in
all patients (28.2% versus 14.2%; P < 0.0001). It also
resulted in an increase in median progression-free survival by
4.9 months (6.1 months versus 11 months), which was
associated with improved overall survival (hazard ratio 0.674)
in the combination arm relative to paclitaxel monotherapy,
although this difference did not reach statistical significance.
Furthermore, a pilot study conducted in patients with inflam-
matory breast cancer demonstrated a decrease in tumour cell
VEGFR2 (KDR) phosphorylation and an increase in apop-
tosis after a single cycle of bevacizumab therapy. This
response was maintained with the addition of chemotherapy.
Results from other trials of bevacizumab are awaited,
including studies evaluating neoadjuvant and adjuvant use of
this agent, and promising results are emerging for patients
with renal cell, colorectal, brain and lung cancers.
In a neoadjuvant study 39 patients with locally advanced
breast cancer were treated with docetaxel with or without
bevacizumab. There were five complete clinical responses
and 24 partial responses, and the therapy was generally well
tolerated. Recently, new results for the combination of
bevacizumab with doxorubicin and docetaxel in the treatment
of inflammatory breast cancer were reported [98]. After
treatment, eight out of 13 patients experienced a confirmed
partial response, with evidence of a decrease in vascular
permeability on dynamic contrast-enhanced magnetic
resonance imaging. An ongoing trial plans to evaluate the
efficacy of bevacizumab in the adjuvant setting with low dose
of methotrexate and cyclophosphamide for cases with
residual cancer after neoadjuvant chemotherapy. There is
also a planned Eastern Cooperative Oncology Group
adjuvant feasibility trial, which will evaluate bevacizumab in
combination with dose-dense doxorubicin and cyclophos-
Available online http://breast-cancer-research.com/content/9/6/216
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breast cancer.
Bevacizumab has a relatively long half-life, which allows inter-
vals between intravenous administrations of up to 3 weeks.
The tolerability profile of bevacizumab is generally acceptable
in clinical trials, and the drug can readily be delivered with
other chemotherapeutic agents that, in some circumstances,
may be synergistic. Although phase I trials suggested no
dose-limiting toxicity, common adverse events of any severity
in patients include asthenia, adnominal pain, headache,
hypertension, diarrhoea, nausea, vomiting, anorexia, stomatitis,
constipation, upper respiratory infection, epistaxis and
proteinuria. Most adverse events were mild to moderate in
severity, and events such as hypertension, haemorrhage, or
proteinuria were clinically manageable. Thus, bevacizumab
provides a highly effective addition to standard chemo-
therapeutic regimens in several common solid tumours.
Tyrosine kinase inhibitors of VEGF
Several receptor tyrosine kinase inhibitors (TKIs) that target
the tyrosine kinase portion of VEGFR1 and VEGFR2 have
been developed that are being investigated [100,101]. The
orally administered VEGFR2 inhibitor ZD6474 was generally
well tolerated but exhibited little activity in patients with
refractory metastatic breast cancer [102]. A variety of other
small molecule TKIs targeting the VEGFRs are being
evaluated, as are ribozyme (catalytic RNA molecules that
specifically cleave VEGFR mRNAs) and antisense strategies.
VEGF is regulated by other transmembrane receptor tyrosine
kinases, the most relevant of which in breast cancer is the
human epidermal growth factor receptor (HER)1 and HER2
(c-erbB-2,  neu) [103-105]. Thus, attenuation of VEGF
signalling and therapeutic synergy might be achieved through
interference in these other receptor pathways with agents
such as trastuzumab in combination with anti-VEGF therapy.
The validity and potential of this strategy is supported by the
positive correlation between HER2 and VEGF expression in a
large cohort of breast cancers [106] and results from a phase
I trial of trastuzumab and bevacizumab [107] that indicated a
clinical response in five out of nine patients.
Inhibition of the VEGFR mRNA has been attempted both with
ribozyme (catalytic RNA molecules), which specifically cleave
the mRNAs for the primary VEGFRs [108], and antisense
VEGF [109]. Angiozyme is a synthetic ribosome that cleaves
the mRNA for the receptor VEGFR1/Flt-1. Preclinical studies
confirmed inhibition of both primary tumour growth and
metastasis [109]. In patients with refractory solid tumours, a
phase I trial of angiozyme demonstrated [110] good
tolerability without significant side effects, and phase II trials
are ongoing. However, a phase II trial in breast cancer
provided no evidence of clinical activity [111], although there
was evidence of biological activity, with a decrease in serum
VEGFR1 levels.
Recently, various small molecule TKIs targeting the
VEGFRs and other critical signalling pathways (for
instance, platelet-derived growth factor receptor [PDGFR]
and epidermal growth factor receptor) in angiogenesis
have been developed. Depending on tumour entity, oral
multitargeted TKIs can exert both antiangiogenic and
antitumour activities at the same time. As a consequence,
they may improve the outcome of cancer patients as single-
agent treatment.
A multireceptor targeting agent is PTK787/ZK 222584. It is
a pan-VEGF, PDGFR, c-kit and c-Fos receptor TKI. It
inhibited the growth of a broad panel of carcinomas in
rodent models, with histological examination revealing
inhibition of microvessel formation [112]. Patients with a
variety of advanced cancers have received this agent and it
has been well tolerated. A recent phase I/II study of
PTK787/vatalanib in combination with trastuzumab in patients
with newly diagnosed HER2-positive metastatic breast cancer
has been initiated.
Many extracellular proteolytic enzymes and their inhibitors are
active during angiogenesis. Expression of various matrix
metalloproteinases has been found to be upregulated in
virtually every type of human cancer, and this upregulation
correlates with advanced stage, invasive and metastatic
properties, and poor prognosis in general [113]. Marimastat,
an orally bioavailable hydroxamate, was the most widely
studied. E2196 was a phase III trial of 190 patients with
metastatic breast cancer who had responding or stable
disease after six to eight cycles of first-line chemotherapy for
metastatic disease [114]. Patients were randomly assigned to
receive marimastat or placebo after chemotherapy. There were
no significant differences in median progression-free survival
or overall survival, but important musculoskeletal toxicities
were noted.
Other agents being evaluated in breast cancer include
sunitinib and sorafenib. Future studies are being directed at
evaluating these agents in combination with other targeted
therapies as well as in the first-line metastatic and/or adjuvant
setting. SU11248 (sunitinib malate) is an inhibitor of receptor
tyrosine kinases for VEGFR1, VEGFR2, PDGFR, c-kit, and
Flt-3. In January 2006, this drug was granted approval by the
US Food and Drug Administration for treatment of
gastrointestinal stromal tumour after disease progression on,
or intolerance to, imatinib mesylate, as well as for the
treatment of metastatic renal cell cancer. Sorafenib (BAY 43-
9006) belongs chemically to a class described as bis-aryl
ureas. It was selected for further pharmacological charac-
terization based on potent inhibition of Raf-1 and its
favourable kinase selectivity profile. Sorafenib exhibited
significant activity against several receptor tyrosine kinases,
including VEGFR2, VEGFR3, PDGFR-α, Flt-3, and c-kit. This
molecule is currently being evaluated in phase III clinical trials
for renal cell and hepatocellular carcinomas.
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inhibitors of VEGFR tyrosine kinase activity are being tested
in the breast cancer setting. Also, the combination of anti-
angiogenic drugs with one another and with other biological
agents is also being explored in an attempt to improve
efficacy and to overcome the drug resistance observed in the
initial studies of antiangiogenic agents. In addition, selecting
patients for treatment on the basis of their clinical features
and tumour characteristics may be essential in optimizing
outcomes with these agents.
Novel use of conventional chemotherapy as antiangiogenic
agents
It is likely that over the next few years the designer agents
discussed above will be supplemented by conventional
chemotherapeutic agents, including cyclophosphamide,
paclitaxel, doxorubicin and vincristine, which appear to have
antitumour effects through interfering with new vessel
formation when used at ‘metronomic’ doses. This is where
chemotherapy is administered frequently at low doses, which
avoids myelosuppression and other dose-limiting side effects
and which would otherwise require rest periods, but this
approach inhibits tumour growth indirectly by damaging
endothelial cells. This delivery strategy has several
advantages over the conventional maximum tolerated dose
approach, apart from reduced toxicity, in that a treatment
response should occur irrespective of the resistance profile
of the tumour cell population. Thus far, only a few clinical
trials have tested this antiangiogenic schedule of
chemotherapy [115-118], and the findings of these studies
suggest that tumour associated endothelial cells may be
sensitive to protracted low-dose chemotherapy. Other
common chemotherapeutic agents, for example the
camptothecin analogues, have also been shown to modulate
angiogenesis as a secondary mechanism of action [119].
Placlitaxel, a microtubule inhibitor that is an active agent in
the treatment of many different cancers, was shown to
possess antiangiogenic properties that are independent of its
antiproliferative action in in vivo models [120]. The level of
expression of thymidine phosphorylase, a migration but
nonmitogenic angiogenic enzyme that converts thymidine to
thymine and 2-deoxyribose, may enhance survival in breast
cancer through at least two mechanisms [121-123]. The first
of these is by activation of intravenous 5-fluoruracil or oral
capecitabine through conversion to active metabolites; the
second mechanism is by abrogating thymidine rescue in
methotrexate regimens and therefore salvaging the
methotrexate block on de novo DNA synthesis.
In addition to conventional chemotherapeutic drugs that have
antivascular effects, hormonal therapies such as tamoxifen
may also have antiangiogenetic properties. Oestrogen is
known to enhance VEGF expression (which may be partly
HIF mediated [124]), and tamoxifen inhibits VEGF and FGF
stimulated angiogenesis, resulting in a decrease in
microvessel density and an increase in necrosis in MCF-7
xenografts [125-130]. Tamoxifen may also downregulate the
angiogenic inhibitor thrombospondin [131]. Other drugs that
may be of interest in this setting are the cyclo-oxygenase-2
inhibitors and biphosphonates, which also appear to have
antiangiogenic potency [132-134].
Other targets
At the time of writing there are 30 agents on the National
Cancer Institute website included in antiangiogenesis trials
that interfere with the neovascularization process at many
levels. Many promising novel targets have yet to reach this
stage of development, the discussion of which is beyond the
scope of this review. However, two of these that are of great
interest are agents targeting the TAMs (which act as
‘conductors’ of angiogenesis) and Notch signalling (which is
involved in cell differentiation, proliferation and apoptosis).
TAMs in breast cancers are markers of poor prognosis [135].
Evidence suggests that tumours recruit and use macrophage
functions to promote tumour growth and metastasis. They
achieve this through modulation of immune function, matrix
degradation, growth factor production and angiogenesis.
TAMs are recruited to avascular areas in breast tumours
probably through hypoxic stimulation, in which they can
release a variety of potent angiogenic factors, including
VEGF (itself a chemoattractant for macrophages), thymidine
phosphorylase, cyclo-oxygenase-2 and tumour necrosis factor-
α. Matrix metalloproteinases such as urokinase plasminogen
activator (also a prognostic factor in breast cancer) from
TAMs can further increase local VEGF levels through
cleavage from the matrix. Thus, the multifunctional and pivotal
TAMs are a target for therapy. Indeed, macrophages are
regulated by oestrogen, and crosstalk between the oestrogen
receptor and cytokine-mediated pathways provide a potential
role for selective oestrogen receptor modulators in prevention
and/or treatment of breast cancer [136].
Notch signalling plays an important oncogenic role in breast
tumour development in animal models. It is also significant in
human breast cancers [137], with upregulation of several of
the Notch pathway components occurring in human breast
cancer cells; also, pathway members are expressed by
endothelial cells in breast cancers. The Notch pathway is
critical for angiogenesis, with mutations being associated
with abnormal vascular development. Interestingly, like VEGF,
haploinsufficiency for the endothelial-specific Notch ligand
Delta-like 4 in mice is embryonic lethal. In view of the
significance of Notch signalling in oncogenesis and tumour
neovascularization, the pathway is a promising target for
treatment. The pathway is complex but several points in the
pathway may be target (reviewed by Shi and Harris [137]).
Central to Notch activation is γ-secretase, which cleaves
Notch, allowing its translocation to the nucleus where it
activates target genes. Thus, inhibiting γ-secretase function
would prevent Notch signal transduction; γ-secretase
inhibitors have been developed that perform this function. 
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It has been more than 35 years since Judah Folkman
suggested that the tumour vasculature would be a target for
anticancer therapy, and in the interim there has been a huge
increase in our understanding of the biology underlying
tumour angiogenesis. Unfortunately, early enthusiasm for this
approach based on strong preclinical data has not
transferred simply to the clinic. Nevertheless, the latest
generation of agents provides reason for optimism, such that
antiangiogenic therapies are being integrated into routine
oncology practice. There is still much to learn, with the full
complexity of the mechanisms of tumour neovascularization
and their regulators still to be defined, not only in individual
tumour types but also in individual patients. Thus, more
information in terms of biomarkers that are predictive of
response is required so that tailored treatment can be
offered. A huge amount of data should become available over
the next few years that should help us to use these agents in
the most effective manner.
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